Intelligence Report · ~15 min read

Renal · Phosphate Binder Therapeutic Area Assessment

1 signals · 1 insights · 5 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 67%

Evidence

7 items

Sources

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Renal · Phosphate Binder integrates 1 signals, 1 executive insights, and 5 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

signalJul 12, 2026
FDA Grants AP Status for Calcium Acetate ANDA202420 by Chartwell Molecular
The FDA has granted approval status (AP) for the ANDA202420 application for Calcium Acetate submitted by Chartwell Molecular.
View detail
regulatoryJul 12, 2026
FDA AP — LEUPROLIDE ACETATE (SUPPL)
Application ANDA074728. Sponsor: SANDOZ. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LEUPROLIDE ACETATE.
View detail
regulatoryJul 12, 2026
FDA AP — LEUPROLIDE ACETATE (SUPPL)
Application ANDA075471. Sponsor: MEITHEAL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LEUPROLIDE ACETATE.
View detail
regulatoryJul 12, 2026
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
Application ANDA075327. Sponsor: ANI PHARMS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LEUCOVORIN CALCIUM.
View detail
regulatoryJul 12, 2026
FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL)
Application ANDA200465. Sponsor: MYLAN. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: AMLODIPINE BESYLATE, ATORVASTATIN CALCIUM.
View detail
insightJul 12, 2026
Regulatory Approval of Calcium Acetate Enhances Competitive Dynamics in Renal Market
The FDA's grant of AP status for Calcium Acetate enhances Chartwell Molecular's competitive positioning in the renal market. This development necessitates a careful assessment of its impact on existing phosphate binder products and potential market dynamics. Regulatory context from FDA (FDA AP — CALCIUM ACETATE (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (9 high-relevance).
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 1 risk-calibrated assessments for portfolio review. 5 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

FDA AP — LEUPROLIDE ACETATE (SUPPL)
77%
Application ANDA074728. Sponsor: SANDOZ. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LEUPROLIDE ACETATE.
Source: FDA
View evidence
FDA AP — LEUPROLIDE ACETATE (SUPPL)
77%
Application ANDA075471. Sponsor: MEITHEAL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LEUPROLIDE ACETATE.
Source: FDA
View evidence
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
77%
Application ANDA075327. Sponsor: ANI PHARMS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LEUCOVORIN CALCIUM.
Source: FDA
View evidence
FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL)
66%
Application ANDA200465. Sponsor: MYLAN. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: AMLODIPINE BESYLATE, ATORVASTATIN CALCIUM.
Source: FDA
View evidence
FDA AP — ATORVASTATIN CALCIUM (SUPPL)
66%
Application ANDA205519. Sponsor: SCIEGEN PHARMS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ATORVASTATIN CALCIUM.
Source: FDA
View evidence
Regulatory Approval of Calcium Acetate Enhances Competitive Dynamics in Renal Market
67%
The FDA's grant of AP status for Calcium Acetate enhances Chartwell Molecular's competitive positioning in the renal market. This development necessitates a careful assessment of its impact on existing phosphate binder products and potential market dynamics. Regulatory context from FDA (FDA AP — CALCIUM ACETATE (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (9 high-relevance).
Source: Humanexa Insight
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

FDA Grants AP Status for Calcium Acetate ANDA202420 by Chartwell Molecular
Regulatory Approval

Insights

Regulatory Approval of Calcium Acetate Enhances Competitive Dynamics in Renal Market
Renal · Phosphate Binder

Executive Summary

Key Developments

FDA Grants AP Status for Calcium Acetate ANDA202420 by Chartwell Molecular

FDA AP — LEUPROLIDE ACETATE (SUPPL)

FDA AP — LEUPROLIDE ACETATE (SUPPL)

FDA AP — LEUCOVORIN CALCIUM (SUPPL)

FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL)

Regulatory Approval of Calcium Acetate Enhances Competitive Dynamics in Renal Market

Strategic Implications

Supporting Evidence

FDA AP — LEUPROLIDE ACETATE (SUPPL)

FDA AP — LEUPROLIDE ACETATE (SUPPL)

FDA AP — LEUCOVORIN CALCIUM (SUPPL)

FDA AP — AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM (SUPPL)

FDA AP — ATORVASTATIN CALCIUM (SUPPL)

Regulatory Approval of Calcium Acetate Enhances Competitive Dynamics in Renal Market

Related Intelligence

Signals

Insights